NCT02035124View on ClinicalTrials.gov

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Advanced Prostate Cancer
Interventions
DRUG

BKM 120

DRUG

Cabazitaxel

Trial Locations (3)

33916

Florida Cancer Specialists-South, Fort Myers

37203

Tennessee Oncology PLLC, Nashville

68114

Nebraska Methodist Hospital, Omaha

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT02035124 - Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | Biotech Hunter | Biotech Hunter